



PATENT
Attorney Docket No. CRP-145

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Cohen et al.
SERIAL NO.: 08/851,628 GROUP NO.: 1646
FILING DATE: May 6, 1997 EXAMINER: Romeo, D.
TITLE: NOVEL THERAPIES FOR CHRONIC RENAL FAILURE

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

**SUBMISSION OF PAPER COPY AND/OR COMPUTER READABLE COPY
OF SEQUENCE LISTING FOR INVENTION
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE**

(check and complete this item, if applicable)

1. ☒ This replies to the Patent Office Letter dated August 17, 1998

Note: If these papers are filed before the office letter issues adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

- ☒ A copy of the Patent Office Letter is enclosed.

2. Submitted herewith is/are

(check each item as applicable)

- A. ☒ a paper copy of the Sequence Listing for this application with each sequence assigned a separate identifier.
- B. ☒ a copy, in computer readable form, of the Sequence Listing for this application.

STATEMENT

3. I hereby state that:


(complete applicable items A, B and/or C)

- A. ☒ the content of the paper and computer readable copies submitted herewith are the same.
- B. ☐ the content of the computer readable copy submitted herewith is the same as the Sequence Listing appearing on pages __ to __ of the original specification as filed.
- C. ☐ this submission includes no new matter.


Respectfully submitted,

Date: February 17, 1999
Reg. No. 38,349

Tel. No.: (617) 248-7362
Fax No.: (617) 248-7100



Michael J. Twomey
Attorney for Applicant(s)
Testa, Hurwitz, & Thibault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110



APPLICANT

Application No.: 08/851,628

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: the specification fails to recite the appropriate sequence identifiers at page 16, lines 5-6, where a sequence is discussed.

Applicant Must Provide:

- ☒ An initial ~~or substitute~~ computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial ~~or substitute~~ paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE